Koninklijke Philips (NYSE:PHG) Lowered to Hold at StockNews.com

StockNews.com downgraded shares of Koninklijke Philips (NYSE:PHG) from a buy rating to a hold rating in a research note published on Thursday.

Other equities research analysts have also recently issued reports about the stock. BNP Paribas raised shares of Koninklijke Philips from an underperform rating to a neutral rating in a research report on Tuesday, May 7th. Sanford C. Bernstein upgraded shares of Koninklijke Philips from a market perform rating to an outperform rating in a research note on Monday, May 13th. UBS Group upgraded shares of Koninklijke Philips from a sell rating to a neutral rating in a research note on Tuesday, April 30th. Finally, JPMorgan Chase & Co. upgraded shares of Koninklijke Philips from an underweight rating to a neutral rating in a research note on Tuesday, April 30th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Koninklijke Philips currently has a consensus rating of Hold and a consensus price target of $19.00.

Koninklijke Philips Trading Up 3.0 %

Shares of NYSE:PHG opened at $26.03 on Thursday. The company’s 50-day moving average price is $26.27 and its two-hundred day moving average price is $23.11. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.20 and a quick ratio of 0.78. Koninklijke Philips has a one year low of $17.75 and a one year high of $29.44. The stock has a market capitalization of $23.59 billion, a PE ratio of -27.11, a price-to-earnings-growth ratio of 0.92 and a beta of 0.72.

Koninklijke Philips (NYSE:PHG) last issued its quarterly earnings results on Monday, April 29th. The technology company reported $0.28 EPS for the quarter. Koninklijke Philips had a negative net margin of 4.41% and a positive return on equity of 9.82%. The firm had revenue of $4.49 billion for the quarter. On average, equities analysts forecast that Koninklijke Philips will post 1.51 EPS for the current fiscal year.

Koninklijke Philips Cuts Dividend

The business also recently declared an annual dividend, which was paid on Thursday, May 9th. Investors of record on Friday, May 10th were paid a $0.9154 dividend. The ex-dividend date was Thursday, May 9th. This represents a yield of 3.5%. Koninklijke Philips’s dividend payout ratio (DPR) is currently -95.83%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Capital Analysts LLC grew its stake in Koninklijke Philips by 6.3% in the 4th quarter. Capital Analysts LLC now owns 8,820 shares of the technology company’s stock valued at $206,000 after buying an additional 521 shares during the last quarter. Dorsey & Whitney Trust CO LLC grew its position in shares of Koninklijke Philips by 5.7% during the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 11,374 shares of the technology company’s stock worth $265,000 after purchasing an additional 615 shares in the last quarter. GAMMA Investing LLC grew its position in shares of Koninklijke Philips by 10.8% during the 2nd quarter. GAMMA Investing LLC now owns 7,148 shares of the technology company’s stock worth $180,000 after purchasing an additional 698 shares in the last quarter. Fifth Third Bancorp grew its position in shares of Koninklijke Philips by 34.4% during the 1st quarter. Fifth Third Bancorp now owns 3,008 shares of the technology company’s stock worth $60,000 after purchasing an additional 770 shares in the last quarter. Finally, EverSource Wealth Advisors LLC grew its position in shares of Koninklijke Philips by 13.5% during the 1st quarter. EverSource Wealth Advisors LLC now owns 7,534 shares of the technology company’s stock worth $151,000 after purchasing an additional 897 shares in the last quarter. Institutional investors and hedge funds own 13.67% of the company’s stock.

Koninklijke Philips Company Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.